The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients
Open accessAbstract
We conducted a retrospective study on the long-term effect of mitotane treatment on testicular adrenal rest tumors (TARTs) in five adult patients with classic 21-hydroxylase deficiency. After 60 months of mitotane treatment, a decrease in adrenal steroids was observed in four patients. Testicular ultrasonography showed complete disappearance of TART in two patients, stabilization in two patients and a halving of TART volume in the remaining patient. Sperm count improved notably in two patients who had normal baseline inhibin B levels and small inclusions, thus enabling cryopreservation of the subjects’ semen. Four years of follow-up of these two patients after the withdrawal of mitotane showed no recurrence of TART and persistent normal testicular function. In conclusion, mitotane could be used as a last resort in CAH patients in the cases of azoospermia associated with TARTs but normal inhibin B levels, as it can improve long-term endocrine and exocrine testicular function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, TART showed resolution by ultrasonography in two patients, with improvements in sperm counts that enabled cryopreservation for future use.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [153]
In the citing paper
“A retrospective case series highlights the long-term effects (60-months) of mitotane in five men with classic CAH and TART-associated infertility153.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [153]
In the citing paper
“Mitotane is a highly lipophilic agent that accumulates in adipose tissue and, given its long half-life (median 53 days)154, close monitoring of glucocorticoid therapy is essential as the effects of mitotane can last for several months after discontinuation153.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [153]
In the citing paper
“Adverse effects included weight loss (n = 3), adrenal crises (n = 2), gastrointestinal disturbance with nausea and diarrhoea (causing one patient to discontinue treatment prematurely), and minor hepatic impairment (n = 4, which resolved with treatment discontinuation).”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [153]
In the citing paper
“Given the narrow therapeutic index and toxicity, serum levels of mitotane were closely monitored (aimed at <14 mg/l) with dose titration and the glucocorticoid dose was increased to prevent adrenal insufficiency.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [153]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Mitotane Use in Inoperable Adrenal Cortical Carcinoma
Lubitz, J. A. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220100011003 · Cited by 224
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
High prevalence of reduced fecundity in men with congenital adrenal hyperplasia
Reisch, N., Flade, L., Scherr, M., Rottenkolber, M., Pedrosa Gil, F., Bidlingmaier, M., Wolff, H., Schwarz, H.-P., Quinkler, M., Beuschlein, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1414 · Cited by 170
Falhammar, H., Nyström, H. F., Ekström, U., Granberg, S., Wedell, A., & Thorén, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0828 · Cited by 170
Engels, M., Span, P. N., van Herwaarden, A. E., Sweep, F. C. G. J., Stikkelbroeck, N. M. M. L., & Claahsen-van der Grinten, H. L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00258 · Cited by 163
Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2851 · Cited by 154
Bouvattier, C., Esterle, L., Renoult-Pierre, P., de la Perrière, A. B., Illouz, F., Kerlan, V., Pascal-Vigneron, V., Drui, D., Christin-Maitre, S., Galland, F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4124 · Cited by 116
Self-citationLong Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia
Cabrera, M. S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3070 · Cited by 105
der Grinten, H. L. C., Otten, B. J., Sweep, F. C. G. J., & Hermus, A. R. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.148 · Cited by 97
Cited by
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Novel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 34
“Therefore, while it may have potential to reduce androgen excess, it has no potential to lower glucocorticoid doses, but rather requires increased glucocorticoid dosing [77, 78], which should be closely monitored to prevent the occurrence of adrenal crises [77].”
BackgroundMethodCardiometabolic Aspects of Congenital Adrenal Hyperplasia
Krysiak, R. G., der Grinten, H. L. C., Reisch, N., Touraine, P. A., & Falhammar, H. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae026 · Cited by 26
Self-citationSarafoglou, K., & Auchus, R. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae759 · Cited by 22
“While mitotane has not been studied as primary therapy in 21OHD, the drug has been successfully employed to regress TART and to improve sperm production for cryopreservation in men with 21OHD (32) (Table 1, Fig.”
Metadata
- Authors
- Bachelot, A., Lapoirie, M., Dulon, J., Leban, M., Renard Penna, R., & Touraine, P.
- Affiliations
- Sorbonne Université (FR)
- Hospices Civils de Lyon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- 2Sorbonne Université, Paris, France
- Corresponding author
- Bachelot, Anne
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03
- Volume
- 184
- Issue
- 3
- Pages
- 365-371
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W3119771522
- Cited by
- 19
- References
- 24
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- mitotane, testicular adrenal rest tumor, congenital adrenal hyperplasia, 21-hydroxylase deficiency, azoospermia, sperm count, inhibin B, testicular function, tumor regression, sperm cryopreservation
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adrenal Rest Tumor, Adult, Humans, Male, Mitotane, Retrospective Studies, Testicular Neoplasms, Treatment Outcome, Antineoplastic Agents, Hormonal, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients. https://app.cochat.ai/papers/10.1530/eje-20-0787
- The paper
- Bachelot, A., Lapoirie, M., Dulon, J., Leban, M., Renard Penna, R., & Touraine, P. (2021). Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients. European Journal of Endocrinology. https://doi.org/10.1530/eje-20-0787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.